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Abstract 
Background 
Accelerated induction regimens of infliximab have been proposed to improve response rates 
in patients with steroid refractory acute severe colitis.  
Aims 
We aimed to determine differences in outcome for acute severe ulcerative colitis between 
accelerated and standard-dose infliximab. 
Methods 
We collected data on hospitalised patients receiving differing regimens of rescue therapy for 
steroid refractory Acute Severe Ulcerative Colitis. Our primary outcome was 30-day 
colectomy rate. Secondary outcomes were colectomy within index admission, 90 days and 12 
months. We used propensity score analysis with optimal calliper matching using a priori 
defined high-risk covariates to reduce potential provider selection bias. 
Results 
We included 131 patients receiving infliximab rescue therapy; 102 patients received standard 
induction and 29 received accelerated induction. In the unmatched cohort, there was no 
difference by type of induction in 30-day colectomy rates (18% vs. 20%, p=0.45), colectomy 
during index admission (13% vs. 20%, p = 0.26) or overall colectomy (20% vs. 24%, p= 
0.38).  
In the propensity score-matched cohort of 52 patients, 30-day colectomy (57% vs. 27%, p = 
0.048) and index admission colectomy (53% vs. 23%,p =0.045) rates were higher in those 
receiving standard induction compared to accelerated induction but there was no difference in 
overall colectomy rates between the 2 groups (57% vs. 31%, p =0.09). There was no 
significant difference in length of stay or in complication and infection rates. 
Conclusion 
In a propensity score matched cohort, steroid refractory Acute Severe Ulcerative Colitis 
patients, short-term, but not long-term, colectomy rates appear to be lower in those receiving 
accelerated induction regimen.  
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Introduction 
Acute severe ulcerative colitis  is a medical emergency with up to 30% of patients requiring 
colectomy during their index admission(1,2) and is associated with a mortality of up to 2.9% 
in peripheral centres and about 1% in specialist inflammatory bowel disease (IBD) units (3). 
Acute severe ulcerative colitis  is traditionally defined by the Truelove and Witt’s criteria (4), 
which combines frequency of bloody stools (≥6 per day) with at least one marker of systemic 
toxicity: pulse rate >90 bpm, temperature >37.8 °C, haemoglobin <105 g/L and/or an ESR 
>30 mm/h. ASUC requiring hospitalization  occurs in 10-25% at diagnosis and in  20-30% 
during the disease course of ulcerative colitis (5,6).  
Intravenous corticosteroids remain the cornerstone of first-line therapy for acute severe 
ulcerative colitis. A meta-analysis of cohort studies and randomized trials, published in 2007, 
examined response to corticosteroids in acute severe ulcerative colitis. The authors reported a 
pooled response rate to intravenous steroids of 67%, indicating that up to 40 % of patients fail 
to respond (7).  Over the last decade, in patients failing corticosteroids, rescue therapies 
including ciclosporin and infliximab (1–3) have been used as an option to avoid colectomy . 
While there is no difference in response rates between infliximab and cyclosporine (8–10), a 
majority of clinicians now appear to favour infliximab mainly citing convenience and safety 
(11).   
Despite use of rescue therapies a significant proportion of patients still undergo 
colectomy(12). The data on rescue therapies indicate that the rates of non-response to 
infliximab rescue vary from 40-55% (8–10). Reasons for non-response may include patient 
and disease factors or treatment factors such as timing of rescue and dosing schedules. A key 
and unanswered question remains the optimal dosing strategy of infliximab in steroid-
refractory acute severe ulcerative colitis. Current regimens have extrapolated dosing 
schedules for management of moderate-to-severe disease in an outpatient clinic setting to the 
hospitalised in-patient, and use a standard induction regimen of 5 mg/kg intravenously at 
week 0, 2 and 6.  However, there are multiple reasons why acute severe ulcerative colitis may 
be associated with increased clearance of infliximab. These include hypoalbuminaemia, 
leakage of infliximab itself into the stool, activation of the reticuloendothelial system and 
higher circulating TNF levels.(13–15)  This enhanced clearance of infliximab may also be 
associated with worse clinical outcomes. 
This has led to the concept of ‘accelerated induction  rescue therapy’, where higher dosages 
or increased frequency of induction dosing have been proposed (15). There are no published 
randomised controlled trials on the efficacy and safety of accelerated induction. Although 
there is increasing use of accelerated induction  in clinical practice, the data from the 
published small cohort studies is conflicting (16–18).   Our recent meta-analysis of available 
cohort studies showed no conclusive evidence for benefit of accelerated induction in reducing 
colectomy rates in steroid refractory disease (19). However, the majority of existing studies 
are single centre cohorts with significant limitations including small sample sizes. 
Furthermore, such studies did not take into account provider bias, which could be an 
important determinant in selection of the type of rescue therapy (20). 
We have now performed a multicentre retrospective cohort study in 11 centres in the United 
Kingdom to compare the outcomes of using accelerated induction to standard induction 
regimens for acute severe ulcerative colitis in the real-world setting. We have used propensity 
score matching method to reduce the impact of provider bias in treatment selection.  
 
Methods 
This was a multicentre retrospective cohort study. We included patients with acute severe 
ulcerative colitis meeting modified Trulove and Witts criteria admitted between May 2016 
and May 2018 for intravenous corticosteroids in 11 acute hospitals in UK (6 university 
teaching hospitals and 5 peripheral secondary care hospitals).   
Inclusion and exclusion criteria  
We included consecutive hospitalized patients needing intravenous steroids who received at 
least 3 doses of IV steroids. Physicians completing the case reports assessed them as meeting 
modified Trulove and Witts criteria. We excluded patients with: a diagnosis of inflammatory 
bowel disease unclassified, Crohn’s colitis, infective colitis; coexistent CMV; admission for 
elective surgery; and prior therapy with anti-TNF. 
Study design 
Patients who received infliximab following failure of intravenous rescue therapy were 
stratified into two groups. The standard induction rescue group comprised of patients who 
received a dose of infliximab 5 mg/kg at week 0 and no further doses until two weeks after 
first dose. The accelerated induction group included patients who received at least two doses 
of 5 mg/kg with a second dose received on or before seven days after the first dose  and/or 
those who received 10 mg/kg for their first dose with a further dose within 2 weeks. We 
recorded available data on clinical and laboratory data at baseline, at commencement of 
rescue therapy, 30 days, 90 days, 6 and 12 months. 
Our primary outcome measure was colectomy rate at 30 days. Secondary outcome measures 
were index admission colectomy rates, colectomy rates at 90 days, 6 months and 12 months, 
the length of hospital admission, and adverse events including post-op complications and 
mortality.  
Statistical analysis 
 
Continuous variables were summarised using mean and standard deviation and compared 
using Student’s t test or the Mann Whitney U test. Categorical variables were expressed as 
proportions and analysed by Fisher’s exact test or Chi-squared test as appropriate.  
Propensity score adjusted matching was used to minimise the possibility of provider bias in 
the choice of rescue treatment. Baseline clinical and demographic variables were matched in 
a 1:1 fashion to create a matched cohort with baseline variables which are independent of the 
initial infliximab dose. We ascribed a priori determined factors considered to affect choice of 
rescue therapy including CRP, serum albumin, CRP-albumin ratio, haemoglobin and 
presence of pancolitis in the propensity score matching. Logistic regression was used to 
generate bivariate propensity scores using these variables. We used the greedy matching 
algorithm with the nearest calliper matching neighbour (random order) within a 0.01 
propensity score was selected for the best match in the matched cohort. We confirmed 
balanced co-variates distribution after matching. 
Kaplan-Meier survival curves were plotted for the primary outcome of 30-day colectomy 
rates in both unmatched and matched cohorts between those receiving standard induction 
compared to accelerated induction and the rates compared by log-rank statistic. 
All tests were two-sided and a p-value of <0.05 was considered significant. We used SPSS 
Statistics Version 25 (IBM Corp., Armonk, NY, USA) for analysis. 
As this was retrospective data collection, in accordance with UK Health Research Authority 
guidance, no central ethical committee submission was made. Individual institutions sought 
permissions to conduct a local service evaluation as appropriate.  
Results 
Study cohort 
We included data on 131 patients from 11 centres across UK receiving rescue therapy for 
steroid refractory acute severe ulcerative colitis, of which 102 received standard induction 
regime and 29 received accelerated induction regimen. The baseline characteristics are 
recorded in Table 1.  There were differences in blood parameters between the patients 
receiving standard induction and accelerated induction rescue (Table 2). Patients receiving 
accelerated regimen were more likely to have higher CRP levels, higher CRP/Albumin ratio 
and lower albumin levels at day 1 and day 3 and there were no differences between the 2 
groups in terms of haemoglobin on day 1 or day 3. 
Colectomy rates: entire cohort 
The overall colectomy rate among the 131 patients who received rescue therapy was 29%.  
Table 3 reports the colectomy rates at 30 days, 90 days, 6 month and 12 months in patients 
receiving rescue therapy. There was no significant difference in overall colectomy rates 
between in patient receiving standard induction vs accelerated induction group (p=0.996). 
Table 3 and Figure 1 
Colectomy rates:  propensity score matched cohort 
Using propensity score matching, we included 52 matched patients receiving rescue therapy 
for comparison. The baseline characteristics and blood markers in the cohort are detailed in 
Table 4.  
In the propensity score matched cohort, there was no difference in overall colectomy rates 
between standard induction and accelerated induction groups (57% vs. 31%, p = 0.09), but 
the index admission colectomy (53% vs. 23%, p = 0.045) and 30-day colectomy (57% vs. 
27%, p = 0.048) rates were higher in those receiving standard induction. (Figure 2) 
Duration of hospital stay & Complications 
The mean duration of hospital stay in patients treated with standard induction was 4.4 days 
(SD 1.6) less than patients given accelerated induction rescue therapy (p<0.01) in the 
unmatched cohort.  In the propensity score matched cohort, there was no significant 
difference in length of stay between standard induction and accelerated induction groups 
(23.6 ± 4.3 vs. 19.2 ± 7.1 days, p = 0.09). There was no difference in complication rates 
between the 2 groups (18.6% vs 20.7%, p=0.8) but there was one death in the accelerated 
induction group. (Table 5) 
Discussion 
Despite the increasing use of infliximab rescue therapy in patients failing intravenous 
steroids, a significant proportion of acute severe ulcerative colitis patients do not respond 
adequately to standard induction dosing. Pharmacokinetic data has led to increasing use of 
intensified or accelerated dosing schedules in rescue therapy for acute severe ulcerative 
colitis patients. Our large multicentre retrospective study showed no difference in colectomy 
rates in the overall cohort of patients receiving standard versus accelerated dosing schedules 
but when provider bias was accounted for in the propensity matched cohort, we found a 
reduction in short term colectomy rates in patients receiving accelerated induction. 
The first study to report the potential benefit of more frequent infliximab infusions in acute 
severe ulcerative colitis  patients was from Gibson et al in Ireland (16), who in their cohort of 
50 hospitalised patients with acute severe ulcerative colitis  showed a reduction in short term 
colectomy rates in the 15 patients who received 3 doses of 5mg/kg within 24 days when 
compared to those receiving standard induction regimen (6.7 % vs 40%, p 0.039). This study 
also suggested shortened time to colectomy in those receiving standard regime although the 
long-term colectomy rates were similar. Notably, 38% of these patients had lower endoscopic 
disease severity (Mayo 2), and the authors did not correct for provider bias in the choice of 
regimen. Furthermore, the definition of accelerated dosing in this study did not include the 
need for a further dose seven days after the first dose or increased front loading dose.  
Subsequent studies examining the use of increased frequency of infliximab at 5 mg/kg 
(17,18,21,22) and a recent meta-analysis (19) have not confirmed the benefit as reported by 
Gibson et al. In one study (21), there was an increased risk of colectomy with accelerated 
induction . Our colectomy rates in the overall unmatched cohort mirrors the results from 
these studies showing no additional significant benefit in short term colectomy rates with 
accelerated induction. 
Some studies (21,23) have assessed an early aggressive approach aimed at overcoming 
proposed faecal losses of infliximab using a front-loading higher dose of 10 mg/kg in acute 
severe ulcerative colitis  patients.  In our study, only 4 patients received a higher initial dose 
and hence could not be analysed separately. Results of a randomised controlled trial from 
Australia (ClinicalTrials.gov Identifier: NCT02770040) comparing various dosing strategies 
is eagerly awaited.  
A number of patient and disease related variables have been suggested as high risk for 
needing colectomy in patients with acute severe ulcerative colitis  (24,25). These indices 
were developed in the pre-infliximab rescue therapy era and the relevance of this in patients 
considered for rescue therapy is uncertain. More recently, a number of other patient related 
factors such as serum albumin, serum albumin-CRP ratio and haemoglobin nadir has been 
proposed as predictive risk factors for colectomy at index admission (16,26). We have 
identified CRP-albumin ratio >2 as a predictor for colectomy (unpublished data). However, at 
present there is no consensus on the consistent identification and risk stratification of patients 
not only needing rescue therapy but also those who may potentially benefit from different 
dosing strategies. This lack of consensus inevitably leads to variations in management and 
dosing regimens (27) as seen in in our study. The blood parameters at first and second doses 
of rescue therapy indicates lack of improvement or indeed worsening which along with 
clinical symptom may prompt a second dose as accelerated induction (data on supplementary 
file 1) 
One of the strengths of our study is the attempt to compare the outcomes between the 
different dosing regimens after accounting for the potential bias of baseline clinical and 
demographic variables and the potential impact of these in clinicians’ choice by using a 
propensity score matched method.  Our model incorporated established disease severity 
markers such as CRP, serum albumin, CRP albumin ratio and haemoglobin levels at 
induction and endoscopic disease severity.  This is the first study to report a benefit of 
accelerated induction regimes when taking into the potential for provider bias based on 
differing disease severity.  Nalagatla et al (23) adjusted for the propensity score in their 
multivariable model and found no difference in in hospital colectomy rates (OR 0.70, 95% CI 
0.16-3.01). However, the overall colectomy rates in both groups in this study (8-9%) was 
substantially lower than our study (17-21%). This may be related to overall lower disease 
severity in all parameters in the patients included in this study when compared to our cohort.  
In a study by Shah et al (21), after adjusting for patient and disease related factors and 
provider bias in a propensity score matched model no reduction in colectomy rates was found 
in those receiving higher upfront dosing when compared to standard dosing.  This study only 
included patients from a single centre and differed from ours by including patients with prior 
infliximab exposure before rescue therapy. Furthermore, in this study and in the study by 
Nalagatla et al (23), the endoscopic disease severity of patients in the propensity matched 
cohort was milder (30% having an endoscopic Mayo score of 2) when compared to our study 
where 97% of the included patients in our matched cohort had severe disease (Mayo 3) at 
endoscopy. Thus, our results suggest that early identification of patients with high risk 
features for colectomy may reduce colectomy rates by use of accelerated rescue therapy. 
In the unmatched cohort, the duration of hospital stay was significantly shorter   in those 
receiving standard induction.  In the matched cohort, on the other hand, there was no 
difference in length of stay. Our results were similar to that of Shah et al (21), where the 
median length of stay was identical in those receiving standard induction and accelerated 
induction in the matched cohort.  In that study, in the unmatched cohort there was higher 
complications in the standard dose group when compared to the high doses group a finding 
not seen in our unmatched cohort. However similar to our results in that study the overall 
complication rate including infectious and/or non-infectious complications were not 
significantly higher in the high dose group compared to standard dosing group in the 
propensity matched cohort. Thus, overall accelerated dosing regimens did not seem to 
increase the risk of complications. There was one death in the accelerated induction group as 
a result of post-operative rectal stump leak and sepsis resulting in multiorgan failure.  
We acknowledge that our study has number of limitations. Due to the retrospective nature of 
the study, we were unable to collect every variable each day following admission with acute 
severe ulcerative colitis and were also unable to record the objective assessment of response 
and remission. We also had no data on serum infliximab levels or biomarkers such as faecal 
calprotectin in patients receiving rescue therapy. There is increasing focus on the use of 
therapeutic drug monitoring in IBD patients treated with infliximab and the impact of dose 
optimisation utilizing drug levels on the outcomes could not be ascertained in this study.  
There were significant differences in the unmatched cohort of patients and also heterogeneity 
in dosing regimens and timing indicating variations in practice in the real-world setting. 
Hence although this was a multicentre study and one of the largest to compare rescue therapy 
regimes, our attempt to reduce provider variation by propensity score matching led to a 
relatively small sample size in the matched cohort thus reducing the power of our study for 
the primary outcome and rate of complications. Furthermore, our model cannot account for 
variability in management including dose optimisation during the maintenance period which 
could have affected the outcome. That said, controlling for bias of treatment choice based on 
disease in a multicentre cohort is a major strength of our study. 
Conclusions 
In conclusion, we found that in the overall cohort of acute severe ulcerative colitis patients in 
real world setting receiving rescue therapy infliximab, the initial induction dosing strategy 
did not change the short term or long-term colectomy rates. In a subgroup of patients with 
matched covariates of severity, accelerated induction regimes appears to reduce in-hospital 
and short-term colectomy rates without any increase in complications. The optimal dosing 
regimens and risk stratification of patients needing accelerated dosing regimens needs to be 
evaluated in a prospective study.  
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Tables , Figures and Supplementary files 
Table 1: Baseline characteristics of the cohort of acute severe colitis patients 
Data shown are mean (standard deviation) or n (%) as appropriate 
 Steroid with 
standard rescue 
therapy (102) 
Steroid with 
accelerated 
rescue therapy 
(29) 
Age (mean, SD) 39.0 (17.1) 38.6 (17.2) 
Gender (n, %) Male 59 (58%) 22 (76%) 
Female 43 (42%) 7 (24%) 
Disease duration in years (mean, SD) 4.0 (5.2) 4.2 (6.0) 
Disease location  
(n, %) 
Proctitis (E1) 2 (2%) 0 (0%) 
Left sided colitis 
(E2) 
36 (35%) 4 (14%) 
Extensive Colitis 
(E3) 
64 (63%) 25 (86%) 
Presence of 
Extra-intestinal 
Manifestations 
(n, %) 
Yes 14 (14%) 7(24%) 
No 88 (86%) 22 (76%) 
Presence of 
comorbidity 
Yes 22 (22%) 4 (14%) 
No 80 (78%) 25 (86%) 
Thiopurines at 
admission 
Yes 33 (32%) 11 (38%) 
No 69 (678%) 17 (589%) 
Steroids at 
admission 
Yes 42 (41%) 10 (35%) 
No 60 (59%) 19 (66%) 
Prior Steroids Yes 68 (67%) 15 (52%) 
No 34 (33%) 14 (48%) 
Previous IV 
steroids 
Yes 30 (29%) 7 (24%) 
No 72 (71%) 22 (76%) 
 
 
Mayo Endoscopic 
Score: 
 
Not available 5 0 
2 8 (8%) 0(0%) 
3 89 (87%) 29 (100%) 
5 ASAs at 
admission 
Yes 77 (75%) 19 (66%) 
No 25 (25%) 10 (34%) 
Route of 
admission  
(n, %) 
Emergency 
admission 
66 (65%) 22 (76%) 
Admission from 
Outpatient IBD 
clinics 
29 (28%) 6 (21%) 
Others 7 (7%) 1 (3%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Blood Parameters at admission and day 3 – Unmatched cohort 
 
 Standard Induction 
Group  
(n=102) 
Accelerated induction 
Group 
(n=29) 
 P  
Haemoglobin Day 1 
(Mean± SD) 
122±19 116±19 0.11 
CRP Day 1 
Median (IQR) 
56 ±78 101±36 0.001 
Serum albumin Day 1 
(Mean± SD) 
33±6 30±2 0.006 
Platelet count Day 1 
(Mean± SD) 
458±145 577±133 0.21 
Monocyte count Day 
1 
(Mean± SD) 
1.2±0.6 1.6±0.6 0.73 
CRP/Albumin ratio >2 
Day 1 (n, %) 
61 (59.8) 24 (82.7) 0.03 
Haemoglobin Day 3 
(Mean ± SD) 
116±17 110±16 0.83 
CRP Day 3 
(Median± IQR) 
75± 91 117± 48 0.001 
Serum albumin Day 3 
(Mean± SD) 
31± 6 27 ±2 0.001 
Platelet count Day 3 
(Mean± SD) 
472±150 615± 134 0.001 
CRP/albumin ratio>2 
Day 3 (n, %)  
49 (48.0) 21 (72.4) 0.01 
 
 
 
  
Table 3: Colectomy rates entire cohort 
 
 Steroid with 
standard rescue 
therapy (102) 
Steroid with 
accelerated 
therapy (29) 
p 
30 days 18 (17.6%) 6 (20.7%) 0.45 
90 days 20 (19.6%) 7 (24.1%) 0.38 
6 months 26 (25.5%) 8 (27.6%) 0.49 
12 months 29 (28.4%) 9 (31.0%) 0.99 
 
  
Table 4: Characteristics of Propensity score matched cohort (n=52) 
 
 Standard induction  
N=26 
Accelerated 
induction 
N=26 
p-value 
Age in years 
median(range) 
31 (17-47) 29 (18-43) 0.93 
Gender, n 
        Male 
        Female 
 
14 
12 
 
11 
15 
0.34 
Disease extent, n 
        Pancolitis 
        Left sided 
colitis 
 
23 
3 
 
21 
5 
 
0.96 
Duration of disease 
years median (SD) 
3.2 (4.1) 2.9 (3.9) 1.00 
Prior steroid use, n 
         Yes 
          No 
 
21 
5 
 
19 
7 
 
0.89 
Prior Thiopurine 
Use 
          Yes 
           No 
 
16 
10 
 
11 
15 
 
0.06 
Mayo endoscopic 
scope, (n) 
           Mayo 3 
           Mayo 2 
 
24 
2 
 
26 
0 
 
0.98 
Number of days on 
IV steroids before 
Infliximab, Median 
(range) 
 
4 (2-7) 
 
3 (2-6) 
 
0.91 
CRP at rescue,  
Median (IQR) 
116 (39) 124 (41) 0.76 
Haemoglobin at 
rescue   
Mean (SD) 
108 (2) 99 (2) 0.08 
Albumin at rescue 
Mean (SD) 
29 (3) 26 (2) 0.64 
Platelet count at 
rescue, mean (SD) 
511 (63) 546 (4) 0.07 
Haemoglobin nadir 
<100 g/L at rescue n 
(%) 
18 (69%) 20 (76%) 1.00 
CRP/Albumin ratio 
>2 at rescue n (%) 
24 (92%) 25 (96%) 0.99 
 
Table 5: Duration of Hospital stay and complications  
 Steroid with 
standard rescue 
therapy (102) 
Steroid with 
accelerated 
therapy (29) 
Days of hospital stay unmatched 
cohort (mean, SD) 
14.8 (8.1) 19.2 (5.9) 
Days of hospital stay matched 
cohort (mean, SD)  
23.6(4.3) 19.2(7.1) 
Complications -
infections, post 
op complications 
or mortality (n, 
%) unmatched 
cohort  
Yes 19 (18.6%) 6 (20.7%) 
No 83 (80.4%) 23 (79.3%) 
 
 
  
Figure 1. Kaplan Meier plot for colectomy free survival – accelerated induction vs 
standard induction :Unmatched cohort 
 
 
 
 
  
Figure 2: Kaplan Meier plot for colectomy free survival – accelerated induction vs standard 
induction Matched cohort  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Supplementary table 1: Blood parameters at first and second dose rescue in 
Accelerated induction group (unmatched cohort) 
 First dose rescue (29) Second dose rescue (29) 
Haemoglobin  106 (1) 89 (2) 
CRP  
Median (IQR) 
105 (43) 147(48) 
Serum albumin  
(Mean± SD) 
27 (3) 24 (4) 
Platelet count  
(Mean± SD) 
552 (26) 569 (51) 
CRP/albumin ratio>2 
(n, %)  
27 (93%) 28 (97%) 
 
Supplementary table 2: Blood parameters at first and second dose rescue in the 
accelerated induction group (matched cohort)  
 First dose Rescue (26) Second dose rescue (26)  
CRP   
Median (IQR) 
119 (51) 123 (31) 
Haemoglobin    
Mean (SD) 
99 (2) 87 (2) 
Albumin  
Mean (SD) 
26 (2) 24 (2) 
Platelet count at 
rescue, mean (SD) 
546 (44) 563 (63) 
CRP/Albumin ratio 
>2 (%) 
25 (96%) 25 (96%) 
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